Información del artÃculo
El Texto completo está disponible en PDF
Bibliografía
[1.]
G.L. Mandell, W.A. Petri.
Antimicrobial agents: sulfonamides, trimethroprim-sulfamethoxazole, quinolones, and agents for urinarytract infections.
Goodman and Gilman's basis of therapeutics, 9.a, pp. 1057-1072
[2.]
S.M. Borcherding, R. Stevens, R.A. Nicholas, C.R. Corley, T. Self.
Quinolones: a practical review of clinical uses, dosing considerations, and drug interactions.
J Fam Pract, 42 (1996), pp. 69-78
[3.]
National Committee for Clinical Laboratory Standards.
Performance standards for antimicrobial susceptibility testing. Sixth International Supplement. NCCLS Document, 15 (1995),
[4.]
R. Pallarés, J. Linares, M. Vadillo, C. Cabellos, F. Manresa, P.F. Viladrich, et al.
Resistance to penicillin and cephalosporins and mortality from severe pneumococcal pneumonia in Barcelona, Spain.
N Engl J Med, 333 (1995), pp. 474-480
[5.]
L. Gaztelorrutia, R. Zalacaín, G. Rubio, J.L. Hernández, E. Urra, M. Hernández.
Actualidad de la penicilina en las neumonías neumocócicas extrahospitalarias.
Enferm Infecc Microbiol Clin, 12 (1994), pp. 17-20
[6.]
J. García.
Situación epidemiológica actual y resistencia de los patógenos respiratorios en España.
Med Clin (Barc), 110 (1998), pp. 44-51
[7.]
F. Sánchez, A. Narváez, R. Iglesias, E. García-Oñive, R. Iñíguez, J.F. Sánchez.
Resistencias a penicilina y eritromicina en neumonías neumocócicas extrahospitalarias.
Enferm Infecc Microbiol Clin, 12 (1994), pp. 475
[8.]
D.M. Musher.
Pneumococcal outbreaks in nursing homes.
N Engl J Med, 338 (1998), pp. 1915-1916
[9.]
G.A. Pankuch, M.A. Visalli, M.R. Jacobs, P.C. Appelbaum.
Activities of oral and parenteral agents against penicillinsusceptible and resistant pneumococci.
Antimicrob Agents Chemother, 39 (1995), pp. 1499-1504
[10.]
R. Aguilar, J. Rosendo, I.P. Balcabao, M. Martín, M.J. Giménez, J. Frías.
Pharmacodinamic effects of amoxycillin versus cefotaxime against penicillin-susceptible and penicillin-resistant pneumoccocal strains: a phase I study.
Antimicrob Agents Chemother, 41 (1997), pp. 1389-1391
[11.]
S.W. Schwarzmann.
Novel cost-effective approaches to the treatment of community-acquired infections.
Ann Pharmacother, 32 (1998), pp. S27-S30
[12.]
J. Verhaegen, L. Verbist.
In-vitro activity of 21 beta-lactam antibiotics against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
J Antimicrob Chemother, 41 (1998), pp. 381-385
[13.]
J. Spencer, L. González, R.P. Miler, M.L. Myers.
Treatment of penicillin-resistant pneumococcus with penicillin: a case report.
J Fam Pract, 44 (1997), pp. 499-503
[14.]
J. Liñares, F. Tubau.
Resistencia a cefalosporinas en infecciones por Streptococcus pneumoniae.
Med Clin (Barc), 110 (1998), pp. 21-24
[15.]
M.A. Alonso, M.N. Gutiérrez, J.L. Muñoz, J.A. García.
Resistencia a macrólidos, lincosamidas y estreptograminas en infecciones por Streptococcus pneumoniae.
Med Clin (Barc), 110 (1998), pp. 25-30
[16.]
F. Baquero.
Trends in antibiotic resistance of respiratory pathogens: an analysis and commentary on a collaborative surveillance study.
J Antimicrob Chemother, 38 (1997), pp. 117-132
[17.]
García J y Grupo Español para Vigilancia de Patógenos Respiratorios.
Situación epidemiológica actual y resistencia de los patógenos respiratorios en España.
Med Clin (Barc), 110 (1998), pp. 44-51
[18.]
C. Rodríguez, R. Yáñez, I. Rodríguez, J.J. Picazo.
Resistencia intrínseca de Haemophilus influenzae a los betalactámicos.
Med Clin (Barc), 110 (1998), pp. 52-59
[19.]
E.J. Perea.
Actividad de los macrólidos sobre Haemophilus influenzae: una revisión clínica.
Med Clin (Barc), 110 (1998), pp. 60-64
[20.]
D.C. Hooper.
Expanding uses of fluoroquinolones: opportunities and challenges.
Ann Intern Med, 129 (1998), pp. 908-910
[21.]
T. Alarcón, M. López-Brea.
Mecanismo de acción y resistencias a fluoroquinolonas.
Enferm Infecc Microbiol Clin, 107 (1996), pp. 472-476
[22.]
F. Baquero, M.C. Negri, M.I. Morosini, J. Blázquez.
Antibiotic-selective environments.
Clin Infect Dis, 27 (1998), pp. 5-11
[23.]
J.M. Aguilar, J. Chacón, R. Cantón, F. Baquero.
The emergence of highly fluoroquinolone-resistant Escherichia coli in community-acquired urinary tract infections.
J Antimicrob Chemother, 29 (1991), pp. 349-350
[24.]
J.F. Acar, F.W. Goldstein.
Trends in bacterial resistance to fluoroquinolones.
Clin Infect Dis, 24 (1997), pp. 67-73
[25.]
B. Cooper, M. Lawlor.
Pneumococcal bacteremia during ciprofloxacin therapy with ciprofloxacin.
Am J Med, 89 (1989), pp. 383-384
[26.]
J. Garau.
Papel de las quinolonas en el tratamiento de la neumonía adquirida en la comunidad.
Med Clin (Barc), 110 (1998), pp. 31-35
[27.]
S.J. Martin, J.M. Meyer, S.K. Chuck, R. Jung, C.R. Messick, S.L. Pendland.
Levofloxacin and sparfloxacin: new quinolone antibiotics.
Ann Pharmacother, 32 (1998), pp. 320-326
[28.]
M.A. Cohen, M.D. Huband, J.W. Gage, S.L. Yoder, G.E. Roland, S.J. Gracheck.
In-vitro activity of clinofloxacin, trovafloxacin, and ciprofloxacin.
J Antimicrob Chemother, 40 (1997), pp. 205-211
[29.]
C. Thornsberry, P. Oglivie, J. Kahn, Y. Mauriz.
Surveillance of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the United States in 1996-1997 respiratory season. The Laboratory Investigator Group.
Diagn Microbiol Infect Dis, 29 (1997), pp. 249-257
[30.]
R. Wise, J.M. Adams.
A comparison of the activity of ciprofloxacin and levofloxacin with other agents against respiratory tract pathogens.
J Chemother, 10 (1998), pp. 276-279
[31.]
C. Edlund, S. Sjoestedt, C.E. Nord.
Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora.
Scan J Infect Dis, 29 (1997), pp. 383-386
[32.]
J. George, I. Morrissey.
The bactericidal activity of levoflocain compared with ofloxacin, D-ofloxacin, ciprofloxacin, sparfloxacin and cefotaxime against Streptococcus pneumoniae.
J Antimicrob Chemother, 39 (1997), pp. 719-723
[33.]
P. Gehanno, P. Berche.
and the Sinusitis Study Group. Sparfloxacin versus cefuroxime axetil in the treatment of acute purulent sinusitis.
J Antimicrob Chemother, 37 (1996), pp. 105-114
[34.]
S.C. Chien, F.A. Wong, C.L. Fowler, S.V. Callery-D'Amico, R.R. Williams, R. Nayak, et al.
Double-blind evaluation of the safety and pharmacokinetics multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers.
Antimic Agents Chemother, 42 (1998), pp. 885-888
[35.]
D. Pontani, H. Washton, S. Bouchillon, J. Johnson.
Susceptibility of European respiratory tract isolates to trovafloxacin, ciprofloxacin, clarithromycin, azithromycin and ampicillin.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 413-419
[36.]
R.N. Jones, M.A. Pfaller, G.V. Doern.
Comparative antimicrobial activity of trovafloxacin tested against 3049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season.
Diagn Microbiol Infect Dis, 32 (1998), pp. 119-126
[37.]
K. Waites, E. Brookings, S. Nix, A. Robinson, B. Gray.
Swiatlo. Comparative in vitro activities of four new fluoroquinolones against Streptococcus pneumoniae determined by E-test.
Intern J Antimicrob Agents, 9 (1998), pp. 215-218
[38.]
M.A. Visalli, L. Bajaksouzians, M.R. Jacobs, P.C. Appelbaum.
Comparative activity of trovafloxacin, alone and in combination with other agents, against Gram-negative nonfermentative rods.
Antimicrob Agents Chemother, 41 (1997), pp. 1475-1481
[39.]
J.C. Pechere, T.D. Gootz.
Bacteriological activity of trovafloxacin, a new quinolone, against respiratory tract pathogens.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 405-412
[40.]
L.J.V. Piddock, M. Johnson, V. Ricci, S.L. Hill.
Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract.
Antimicrob Agents Chemother, 42 (1998), pp. 2956-2960
[41.]
T. Alarcón, D. Domingo, N. Prieto, S. Sánchez, M. López-Brea.
Actividad in vitro de la trovafloxacina en 238 patógenos respiratorios.
Rev Esp Quimioter, 11 (1998), pp. 47-51
[42.]
J.A. Hoogkamp-Korstanje.
In-vitro activities of ciprofloxacin, levofloxacin, lomefloxacin, ofloxacin, pefloxacin, sparfloxacin and trovafloxacin against Gram-positive and Gram-negative pathogens from respiratory tract infections.
J Antimicrob Chemother, 40 (1997), pp. 427-431
[43.]
P.M. Roblin, A. Kutlin, M.R. Hammerschlag.
In vitro activitiy of trovafloxacin against Chlamydia pneumoniae.
Antimicrob Agents Chemother, 41 (1997), pp. 2033-2034
[45.]
D. Felmingham, M.J. Robbins, Y. Tesfaslasie, I. Harding, S. Shrimpton, R.N. Gruneberg.
Antimicrobial susceptibility of community-acquired lower respiratory tract bacterial pathogens isolated during the 1995-1996 cold season.
J Antimicrob Chemother, 41 (1998), pp. 411-415
[46.]
J. Schrock, B.A. Hackman, J.F. Plouffe.
Susceptibility of ninety-eight clinical isolates of Legionella to macrolides and quinolones using the E-test.
Diagn Microbiol Infect Dis, 28 (1997), pp. 221-223
[47.]
R. Stahlmann, R. Schwabe.
Safety profile of grepafloxacin compared with other fluoroquinolones.
J Antimicrob Chemother, 40 (1997), pp. 83-92
[48.]
D. Williams, S. Hopkins.
Safety of trovafloxacin in treatment of lower respiratory tract infections.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 454-458
[49.]
Anónimo.
Trovafloxacin.
The Medical Letter on Drugs and Therapeutics, 40 (1998), pp. 30-31
[50.]
P. Ball, L. Mandell, Y. Niki, G. Tillotson.
Comparative tolerability of the newer fluoroquinolone antibacterials.
Drug Safety, 21 (1999), pp. 407-421
[51.]
Anónimo.
Grepafloxacin: a new fluoroquinolone.
The Medical Letter on Drugs and Therapeutics, 40 (1998), pp. 17-18
[52.]
B. O'Doherty, D.A. Dutchman, R. Pettit, A. Maroli.
Randomized, double-blind, comparative study of grepafloxacin and amoxycillin in the treatment of patients with community-acquired pneumonia.
J Antimicrob Chemother, 40 (1997), pp. 73-81
[53.]
C.E. Langan, R. Cranfield, S. Breisch, R. Pettit.
Randomized, double-blind study of grepafloxacin versus amoxycillin in patients with acute excacerbations of chronic bronchitis.
J Antimicrob Chemother, 40 (1997), pp. 63-72
[54.]
B. O'Doherty, R. Daniel.
Treatment of acute exacerbations of chronic bronchitis: comparison of trovafloxacin and amoxicillin in a multicentre, doubleblind, double-dummy study. Trovafloxacin Bronchitis Study Group.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 441-446
[55.]
P. Leophonte, R.J. Baldwin, N. Pluck.
Trovafloxacin versus amoxicillin/clavulanic acid in the treatment of acute exacerbations of chronic obstructive bronchitis.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 434-440
[57.]
S. Chodosh, C.A. DeAbate, D. Haverstock, L. Aneiro.
Church D and the Bronchitis Study Group.
Short-course moxifloxacin therapy for treatment of acute bacterial exacerbations of chronic bronchitis, Respir Med, 94 (2000), pp. 18-27
[58.]
C.D. Marchant, S.A. Carlin, C.E. Johnson, P.A. Shurin.
Measuring the comparative efficacy of antibacterial agents for acute otitis media: the «Pollyana» phenomenon.
J Pediatr, 120 (1992), pp. 72-77
[59.]
J. Spencer, L. González, R.P. Miler, M.L. Myers.
Treatment of penicillin-resistant Pneumococcus with penicillin: a case report.
J Fam Pract, 44 (1997), pp. 499-503
[60.]
H. Seppala, T. Klaukka, J. Vuopio-Varkila, A. Muotiala, H. Helenius.
Lager K and the Finnish Study Group for Antimicrobial Resistance. The effect of changes in the consumption of macrolide antibiotics on erythromyicin resistance in group A streptococci in Finland. Finnish Study group for Antimicrobial Resistance.
N Engl J Med, 14 (1997), pp. 441-446
[61.]
J. Liñares, A.G. De la Campa, R. Pallarés.
Fluoroquinolone resistamce in Streptococcus pneumoniae.
N Engl J Med, 341 (1999), pp. 1546-1548
[62.]
S.R. Norrby.
New fluoroquinolones: towards expanded indications?.
Current Opinion Infect Dis, 10 (1997), pp. 440-443
Copyright © 2000. Elsevier España, S.L.. Todos los derechos reservados
